Barclays analyst initiates Positive coverage on Anteris Technologies, forecasting a 4%-5% U.S. TAVR market share for DurAVR ...
CorMedix Inc.'s DefenCath shows considerable promise in reducing catheter-related bloodstream infections. Click here for this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback